CX Institutional Has $8.06 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

CX Institutional raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 42.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,187 shares of the specialty pharmaceutical company’s stock after buying an additional 18,295 shares during the period. CX Institutional’s holdings in Jazz Pharmaceuticals were worth $8,064,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Philip James Wealth Mangement LLC boosted its position in Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares during the period. State of Alaska Department of Revenue raised its position in shares of Jazz Pharmaceuticals by 75.1% in the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after purchasing an additional 24,850 shares during the period. Inspire Investing LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $689,000. Baird Financial Group Inc. bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $539,000. Finally, Kennedy Capital Management LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $1,100,000. 89.14% of the stock is currently owned by institutional investors.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Phase 3 HERIZON‑GEA‑01 released strong efficacy and safety data for Ziihera (zanidatamab‑hrii) in first‑line HER2+ gastroesophageal adenocarcinoma, including more than two years median overall survival benefit and a claim that Ziihera plus chemo could replace trastuzumab as standard of care; results will be presented as a late‑breaking oral at ASCO‑GI. PR Newswire release
• Positive Sentiment: Multiple outlets frame the Ziihera data as “practice‑changing” for stomach/G E A and as a potential new HER2 agent‑of‑choice, which raises revenue upside and de‑risks Jazz’s oncology franchise in the eyes of investors. BioSpace article FiercePharma article
• Positive Sentiment: Bank of America Securities reaffirmed a Buy on JAZZ, supporting investor confidence and providing analyst backing for the stock after the new data. Globe and Mail / BofA note
• Neutral Sentiment: Technical/market note — JAZZ passing above its 200‑day moving average has been flagged by market commentary, which can attract momentum buyers but is not a fundamental change. Technical note
• Negative Sentiment: Separately, Jazz faced at least one disappointing Phase 3 result (different program) that prompted an earlier intraday sell‑off and media coverage noting the stock decline — this highlights binary clinical risk across Jazz’s pipeline and explains some recent volatility. Investing.com article
• Negative Sentiment: Commentary pieces pointed to mixed data and investor unease around non‑Ziihera results, tempering enthusiasm and keeping upside contingent on regulatory path and commercial rollout. The Pharma Letter

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on JAZZ shares. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. UBS Group restated a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Morgan Stanley upped their price objective on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a report on Monday, November 17th. Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $200.47.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director directly owned 393,332 shares in the company, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,791 shares of company stock valued at $21,991,850 over the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $169.37 on Thursday. The business has a fifty day moving average price of $162.89 and a two-hundred day moving average price of $136.90. The stock has a market capitalization of $10.29 billion, a PE ratio of -27.90, a P/E/G ratio of 0.78 and a beta of 0.27. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.